Discounted Cash Flow (DCF) Analysis Unlevered

X4 Pharmaceuticals, Inc. (XFOR)

$0.8917

-0.03 (-3.10%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 0.8917 | undervalue

Operating Data

Year
A/P
2017
Actual
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 0.8,917
Beta 0.728
Diluted Shares Outstanding 25.75
Cost of Debt
Tax Rate -0.02
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 7.314
Total Debt 0.80
Total Equity 22.96
Total Capital 23.76
Debt Weighting 3.35
Equity Weighting 96.65
Wacc

Build Up Free Cash

Year
A/P
2017
Actual
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 0.00%0.00%0.00%-0.24%-0.02%-0.05%-0.05%-0.05%-0.05%-0.05%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -0.04-0.03-0.17-1.36------
UFCF ----------
WACC
PV UFCF --------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 7.24
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -80.99
Equity Value -
Shares Outstanding 25.75
Equity Value Per Share -